Outgoing CORC Chair Marcus Snow, MD, FACR, and the College look back on the tremendous achievements made during the past three years, including pandemic care guidance, improved patient access to care and direction through new biosimilars choices.
FDA Approves Canakinumab to Treat Gout Flares
Canakinumab has received FDA approval for the treatment of patients with acute gout flares.
Concerning the Back: Updates in AS & nr-axSpA
During the 19th Annual Johns Hopkins Advances in the Diagnosis and Treatment of the Rheumatic Diseases Symposium, Dr. Atul Deodhar provided an overview on axial spondyloarthritis (axSpA) and non-radiographic axSpA, with helpful insights into the diagnosis and care of patients with these conditions.
FDA Accepts NDA for Investigational RA Agent
The FDA has accepted an investigational new drug application (NDA) for MYMD-1, an oral tumor necrosis factor-α inhibitor for patients with rheumatoid arthritis.
When Is Arthroplasty Recommended? New ACR/AAHKS Guideline Offers Considerations for Timing of Elective Hip or Knee Arthroplasty
The ACR released a new arthroplasty guideline in an effort to remedy significant & detrimental delays faced by osteoarthritis or osteonecrosis patients who require surgical intervention.
Are We Making Progress in Treating Lupus? Clinical Insights from Dr. Michelle Petri
At the 19th Annual Advances in the Diagnosis and Treatment of the Rheumatic Diseases course, Dr. Michelle Petri gave a presentation concerning the overall state of lupus treatment outcomes in the U.S.
Criteria, Guidelines & Medications: Updates in the World of Vasculitis
The 19th Annual Johns Hopkins Advances in the Diagnosis and Treatment of Rheumatic Diseases Symposium session titled, Updates on Vasculitis provided an overview of the latest information on vasculitis diagnosis and treatment.
Belimumab vs. Oral Immunosuppressants: Infection Risk in Patients with Non-Renal SLE
Materne et al. aimed to compare the risk of infection among patients with non-renal SLE using the injectable immunosuppressant belimumab vs. an oral immunosuppressant, azathioprine, mycophenolate or methotrexate.
Ask Congress to Support Complexity Add-on Code
Implementation of the G2211 add-on code for evaluation and management services is included in the CY 2024 Medicare Physician Fee Schedule, barring further delays. Ask your lawmakers to support timely implementation and patient access to complex care.
We Want You: Your Role in the CPT Valuation Process
Accurate reimbursement for rheumatology services ensures rheumatologists can run successful practices and provide needed care, but only if they speak up through survey input to explain how much that care costs. Here’s how to participate in the process when rheumatology CPT codes come up for review.
- « Previous Page
- 1
- …
- 53
- 54
- 55
- 56
- 57
- …
- 812
- Next Page »